Host: The Japanese Society of Toxicology
For development of next generation vaccines including COVID-19 vaccines, vaccine adjuvants targeting PRRs, which is related to the innate immune system, have shown great promise in their ability to enhance responses to component vaccines. However there is also a risk to induce massive unexpected inflammation by using these adjuvants. Thus it is important to carefully select the correct pre-clinical model to evaluate the safety and efficacy of the adjuvanted vaccines.
In this presentation, we will introduce our recent data regarding development of vaccines and adjuvants in non-human primate model and discuss about how we can use this model more efficiently for immunotoxicology assessment in future.
